Verdict: Justified

Key finding: Q3 revenue $524.4M beat the $500.4M consensus. BRINSUPRI hit $400.1M (+29% q/q), and 2026 guidance was raised to $1.35–1.40B. The launch is working. The stock is still −54% from its $212.75 high, a fall driven by two failed expansion trials and doubts about the launch pace, not by BRINSUPRI missing.

Scorecard

Ticker Rev last Q ($M) Rev YoY last Q Rev YoY prior Q Gross margin (last Q, trend) Op margin EPS last Q vs yr ago P/S Mkt cap 1-mo price %
INSM (Q3-26) 524.4 +268.5% +296.1% 85.1% (up from 79.4%) −17.0% −0.46 vs −1.75 13.9x $21.2B −17.6%
UTHR (Q2-26) 783.3 −1.9% −1.6% 87.3% (flat) +42.2% 7.27 vs 6.41 8.0x $25.2B +20.8%
LQDA (Q2-26) 171.7 +1,842.7% — 93.3% (up) +49.8% 0.74 vs −0.49 9.1x $4.1B −37.9%
VRTX (Q2-26) 3,333.9 +12.5% +7.8% 85.3% (flat) +37.4% 4.31 vs 3.99 10.6x $134.3B +0.4%

INSM is the growth leader of the group, but the only one losing money and the most expensive on sales: revenue +268% y/y, operating margin −17% against +37% to +50% for peers, P/S 13.9x against 8.0–10.6x. Percentage growth is slowing as the base grows (+296% to +268%). The raised guidance implies Q4 BRINSUPRI of about $432–482M, or +8% to +20% q/q, after +29% in Q3 (calculated from the company's numbers). UTHR and LQDA overlap with the TPIP pipeline (inhaled treprostinil for PAH and PH-ILD). VRTX is the large respiratory biotech reference.

Move

Catalyst

Q3 2026 results (8-K, 10/29):
- Total revenue $524.4M (+268% y/y) against a $500.4M consensus (FMP).
- BRINSUPRI $400.1M ($398.1M US), +29% q/q. ARIKAYCE $124.4M (+9% y/y).
- 2026 guidance raised: BRINSUPRI $1.35–1.40B (from $1.25–1.40B); ARIKAYCE $460–470M (from $450–470M). Peak-sales targets unchanged: BRINSUPRI >$7B, TPIP >$6B, ARIKAYCE >$1B.
- EPS −$0.46 against −$0.38 consensus (a miss). R&D was $270.0M (from $186.4M a year ago) and SG&A $253.0M (from $186.4M). Net loss $100.3M; cash and securities about $1.1B; 219.3M shares outstanding.
- Pipeline:
- TPIP PALM-ILD is over 35% enrolled, with enrollment completing in 1H 2028.
- PALM-PAH (first patient July 2026) and PALM-PPF (September 2026) have started; the IPF Phase 3 starts in 1H 2027.
- ARIKAYCE's sNDA for MAC lung disease has Priority Review, with a PDUFA date of 1/28/2027.
- BRINSUPRI launched in Japan (10/19).
- Ownership: Duquesne Family Office (Druckenmiller) 13F filings on SEC EDGAR show:
- A build from 20K shares (Q3-24) to a 2.42M-share peak worth $349M in Q3-25 (about 8.6% of the 13F).
- Cuts to 1.48M shares (Q4-25, −39%) and 1.15M (Q1-26, −22%).
- In Q2-26, an increase to 1.42M shares (+23%) plus calls on 1.35M shares ($144M notional). That is the largest share-equivalent exposure it has reported. The Q3-26 13F is due in mid-November.

Sector

Risks

Judgement

Justified. Q3 confirms the core thesis. BRINSUPRI grew 29% q/q to $400M, revenue beat by about 5%, and guidance was raised. That comes after the stock had fully retraced the August post-Q2 gap and returned to its June lows. The 54% drawdown came from failed expansion trials and launch-pace doubts, and this quarter answers the launch-pace part. Against it: the EPS miss from rising R&D, the implied Q4 slowdown, cash burn, and BRINSUPRI's reliance on a single indication until TPIP reads out in 2028+. The business is on track; the risk is in spending and timing, not demand.

Sources